or Try an Advanced Search...

    Technical Analysis for OCGN - Ocugen, Inc.

    Grade Last Price % Change Price Change
    F 0.92 5.14% 0.04
    OCGN closed up 5.14 percent on Wednesday, November 20, 2024, on 1.17 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical OCGN trend table...
    Date Alert Name Type % Chg
    Outside Day Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction 5.14%
    Stochastic Reached Oversold Weakness 5.14%
    Down 3 Days in a Row Weakness 5.14%
    Oversold Stochastic Weakness 5.14%
    MACD Bearish Signal Line Cross Bearish 0.80%
    50 DMA Resistance Bearish -2.14%
    Fell Below 20 DMA Bearish -2.14%
    Older End-of-Day Signals for OCGN ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above Previous Day's High about 21 hours ago
    Outside Day about 21 hours ago
    Up 5% about 21 hours ago
    2x Volume Pace about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    OCGN Chart by TradingView
    Basic chart:

    Profile

    Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Eye Ophthalmology Eye Diseases Vision Diabetic Retinopathy Retina Blindness Host Disease Innovative Therapies Retinitis Retinopathy Graft Versus Host Disease Retinitis Pigmentosa

    Is OCGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
    Nov 19 Ocugen reports positive data for OCU400, OCU410
    Nov 19 Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    Nov 14 Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
    Nov 14 Ocugen: Q3 Earnings Snapshot
    Nov 9 Q3 2024 Ocugen Inc Earnings Call
    Nov 9 Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
    Nov 8 Ocugen (OCGN) Q3 2024 Earnings Call Transcript
    Nov 8 Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
    Nov 8 Ocugen reports Q3 results
    See more OCGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.105
    52 Week Low 0.36
    Average Volume 3,734,579
    200-Day Moving Average 1.29
    50-Day Moving Average 0.99
    20-Day Moving Average 0.96
    10-Day Moving Average 0.98
    Average True Range 0.08
    RSI (14) 45.36
    ADX 16.73
    +DI 15.50
    -DI 20.25
    Chandelier Exit (Long, 3 ATRs) 0.89
    Chandelier Exit (Short, 3 ATRs) 1.09
    Upper Bollinger Bands 1.07
    Lower Bollinger Band 0.86
    Percent B (%b) 0.28
    BandWidth 21.97
    MACD Line -0.02
    MACD Signal Line -0.01
    MACD Histogram -0.0066
    Fundamentals Value
    Market Cap 235.6 Million
    Num Shares 257 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -2.87
    Price-to-Sales 25069.32
    Price-to-Book 2.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.05
    Resistance 3 (R3) 1.04 0.99 1.03
    Resistance 2 (R2) 0.99 0.96 0.99 1.02
    Resistance 1 (R1) 0.95 0.94 0.97 0.96 1.01
    Pivot Point 0.90 0.90 0.91 0.91 0.90
    Support 1 (S1) 0.87 0.87 0.89 0.88 0.82
    Support 2 (S2) 0.82 0.85 0.82 0.82
    Support 3 (S3) 0.78 0.82 0.81
    Support 4 (S4) 0.79